Literature DB >> 29749947

Incidence, Predictors, and Significance of Ventricular Arrhythmias in Patients With Continuous-Flow Left Ventricular Assist Devices: A 15-Year Institutional Experience.

Brian D Greet1, Deep Pujara1, David Burkland1, Mark Pollet1, Deepthi Sudhakar1, Francia Rojas2, Briana Costello1, Alexander Postalian1, Zachary Hale1, Ben Jenny1, Carol Lai1, Kenneth Igbalode1, Divesh Wadhera1, Ajith Nair1, Masahiro Ono3, Jeffrey Morgan3, Leo Simpson1, Andrew Civitello1, Jie Cheng2, Nilesh Mathuria4.   

Abstract

OBJECTIVES: The aim of this study was to evaluate the incidence, predictors, and associated mortality of pre-implantation, early, and late ventricular arrhythmias (VAs) in patients receiving continuous-flow left ventricular assist devices (CFLVADs).
BACKGROUND: VAs are common both pre- and post-implantation of left ventricular assist devices. Limited data exist on their prognostic impact in contemporary CFLVADs.
METHODS: A retrospective review was performed to identify patients who underwent CFLVAD implantation between 2000 and 2015 with 2 years of follow-up. All VAs, defined as ventricular fibrillation, ventricular tachycardia lasting >30 s, or a ventricular rhythm requiring defibrillation, were analyzed. VAs occurring within 30 days of implantation were defined as early. Recorded outcomes included death and receipt of cardiac transplant.
RESULTS: A total of 517 patients were included for analysis. Early VAs were associated with a significant reduction in survival (hazard ratio: 1.83; 95% confidence interval: 1.28 to 2.61; p = 0.001) compared with patients with late or no VAs. Pre-implantation variables independently predictive of early VAs included prior cardiac surgery (odds ratio: 1.90; 95% confidence interval: 1.09 to 3.32; p = 0.023) and pre-CFLVAD ventricular tachycardia storm (odds ratio: 3.15; 95% confidence interval: 1.49 to 6.69; p = 0.003). The incidence of early VAs from 2000 to 2007 was as high as 47%, whereas the highest incidence from 2008 to 2015 was <22%.
CONCLUSIONS: VAs within 30 days after CFLVAD implantation are associated with an increased risk for death. Predictors of early VAs include prior cardiac surgery and pre-CFLVAD ventricular tachycardia storm. Temporal trends have shown a decrease in VA from 2000 to 2015. Strategies to reduce arrhythmia burden shortly after CFLVAD implantation warrant further investigation.
Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiac arrhythmia; continuous-flow left ventricular assist device; left ventricular assist device; ventricular arrhythmia; ventricular fibrillation; ventricular tachycardia

Mesh:

Year:  2017        PMID: 29749947     DOI: 10.1016/j.jacep.2017.11.001

Source DB:  PubMed          Journal:  JACC Clin Electrophysiol        ISSN: 2405-500X


  4 in total

1.  ICD shocks in LVAD patients are not associated with increased subsequent mortality risk.

Authors:  Aswini Kumar; Varun Tandon; David M O'Sullivan; Edmond Cronin; Jason Gluck; Jeffrey Kluger
Journal:  J Interv Card Electrophysiol       Date:  2019-09-10       Impact factor: 1.900

2.  A Review of New-Onset Ventricular Arrhythmia after Left Ventricular Assist Device Implantation.

Authors:  Jianwei Shi; Xinyi Yu; Zhigang Liu
Journal:  Cardiology       Date:  2022-04-28       Impact factor: 2.342

3.  Clinical characteristics and outcomes of patients with ventricular arrhythmias after continuous-flow left ventricular assist device implant.

Authors:  Simone Gulletta; Anna Mara Scandroglio; Luigi Pannone; Giulio Falasconi; Giulio Melisurgo; Silvia Ajello; Giuseppe D'Angelo; Lorenzo Gigli; Felicia Lipartiti; Eustachio Agricola; Elisabetta Lapenna; Alessandro Castiglioni; Michele De Bonis; Giovanni Landoni; Paolo Della Bella; Alberto Zangrillo; Pasquale Vergara
Journal:  Artif Organs       Date:  2022-03-21       Impact factor: 2.663

4.  Association between early ventricular arrhythmias and mortality in destination vs. bridge patients on continuous flow LVAD support.

Authors:  Zeina Jedeon; Rebecca Cogswell; Jessica Schultz; Lisa Von Wald; Ranjit John; Henri Roukoz
Journal:  Sci Rep       Date:  2021-09-28       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.